Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Treatment Resistant Depression - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape. Treatment resistant depression (TRD) is an episode of major depressive disorder that does not respond to an antidepressant medication. Symptoms include difficulty concentrating, fatigue, insomnia, overeating or appetite loss and persistent aches or pains, headaches, cramps, or digestive problems. Treatment includes antidepressant from a different drug class, antipsychotic medication, electroconvulsive therapy (ECT) and vagus nerve stimulation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Treatment Resistant Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Treatment Resistant Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 6 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Treatment Resistant Depression. Treatment Resistant Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Treatment Resistant Depression (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Treatment Resistant Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Treatment Resistant Depression (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Treatment Resistant Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Treatment Resistant Depression Overview 7 Therapeutics Development 8 Pipeline Products for Treatment Resistant Depression - Overview 8 Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9 Treatment Resistant Depression - Therapeutics under Development by Companies 10 Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes 11 Treatment Resistant Depression - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Treatment Resistant Depression - Products under Development by Companies 15 Treatment Resistant Depression - Products under Investigation by Universities/Institutes 16 Treatment Resistant Depression - Companies Involved in Therapeutics Development 17 Addex Therapeutics Ltd 17 Amorsa Therapeutics Inc. 18 Avanir Pharmaceuticals, Inc. 19 Axsome Therapeutics Inc 20 Biohaven Pharmaceutical Holding Company Limited 21 Eli Lilly and Company 22 Evotec AG 23 Johnson & Johnson 24 Otsuka Holdings Co., Ltd. 25 Relmada Therapeutics, Inc. 26 Reviva Pharmaceuticals Inc. 27 Sumitomo Dainippon Pharma Co., Ltd. 28 Takeda Pharmaceutical Company Limited 29 Treatment Resistant Depression - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 39 (bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 (dextromethorphan + quinidine sulfate) - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AMS-410 FA - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 AMS-520 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AVP-786 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 CX-157 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 DSP-1200 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 esketamine hydrochloride - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 EVT-100 Series - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 LY-341495 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 REL-1017 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 riluzole - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 TAK-653 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 VU-0431316 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Treatment Resistant Depression - Dormant Projects 69 Treatment Resistant Depression - Discontinued Products 70 Treatment Resistant Depression - Product Development Milestones 71 Featured News & Press Releases 71 Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression 71 Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 71 Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 72 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development for Treatment Resistant Depression, H2 2016 8 Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H2 2016 17 Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016 18 Treatment Resistant Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 19 Treatment Resistant Depression - Pipeline by Axsome Therapeutics Inc, H2 2016 20 Treatment Resistant Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 21 Treatment Resistant Depression - Pipeline by Eli Lilly and Company, H2 2016 22 Treatment Resistant Depression - Pipeline by Evotec AG, H2 2016 23 Treatment Resistant Depression - Pipeline by Johnson & Johnson, H2 2016 24 Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 25 Treatment Resistant Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016 26 Treatment Resistant Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 27 Treatment Resistant Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 28 Treatment Resistant Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 38 Treatment Resistant Depression - Dormant Projects, H2 2016 69 Treatment Resistant Depression - Discontinued Products, H2 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.